Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

3
China’s long march for the soul of the nation’s digital future faces an ever-shifting end point

2018-05-27 scmp
Chinese semiconductor companies are up against a formidable Intel-Microsoft alliance that has ring fenced an eco-system and peripheral sub-sectors of hardware producers, chip designers, software and app developers
HUWHF 0700 0001

0
Harbour's Santos bid the first major test for Dutton's new department

2018-05-22 theage.com.au
Harbour Energy’s China-backed takeover of Santos will be the first major test for Peter Dutton’s Department of Home Affairs’ Critical Infrastructure Centre amid concerns over ownership of key Australian natural resources.
DUETF 0001 DUE

0
Harbour's Santos bid the first major test for Dutton's new department

2018-05-22 smh.com.au
Harbour Energy’s China-backed takeover of Santos will be the first major test for Peter Dutton’s Department of Home Affairs’ Critical Infrastructure Centre amid concerns over ownership of key Australian natural resources.
DUETF 0001 DUE

0
Flash - 'Superman': Hong Kong's richest tycoon Li Ka-shing - France 24

2018-05-10 france24
Hong Kong tycoon Li Ka-shing, 89, who officially retired Thursday, started his career selling plastic flowers and spent seven decades building a vast business empire spanning from container ports to telecommunications.
0001

0
Investors in Li Ka-shing companies now face the big unknown of second generation leadership

2018-03-21 scmp
Conglomerates build by charismatic tycoons often don’t fare so well under second generation leadership who’ve been groomed for the role but lack street smarts
SWRAY SWRBY SWRBF SWRAF 0001

3
Billionaire Li Ka-shing retires

2018-03-17 thestar.com.my
HONG KONG: Li Ka-shing (pic), a wartime refugee who used to sweep factory floors in Hong Kong for a living, retired after a career spanning more than half a century amassing one of Asia’s biggest fortunes from building skyscrapers to selling soap bars.
HCS.PRB HUWHF HGKGF HGKGY CKHUY HUSKF HCS 0001 DUE HSB HSE 0005 CKHUF HSEA HSEB HSBC.PRA DUETF HSBC HBCYF

0
From factory worker to iconic billionaire: Li Ka-shing's success story

2018-03-16 channelnewsasia
HONG KONG: Li Ka-shing's rise from penniless immigrant in 1940 to billionaire tycoon is the consummate success story in Hong Kong, a city which progressed alongside him from trading outpost to one of the world's biggest financial centers.
SWRAY HUWHF SWRBY CKHUF CKHUY SWRBF SWRAF 0001

0
'Superman' retires: Hong Kong tycoon Li Ka-shing to step down

2018-03-16 telegraph.co.uk
Hong Kong's richest man, Li Ka-shing, has finally stepped down from his business empire at the age of 89, as one of the world's most storied tycoons brings his career to a close almost 70 years after founding his first company.
0001

0
'Superman' retires: Hong Kong tycoon Li Ka-shing to step down

2018-03-16 yahoo
Hong Kong's richest man, Li Ka-shing, has finally stepped down from his business empire at the age of 89, as one of the world’s most storied tycoons brings his career to a close almost 70 years after founding his first company.
0001

0
A factory worker at 13, Hong Kong's iconic billionaire Li Ka-shing retires

2018-03-16 reuters
HONG KONG (Reuters) - Li Ka-shing’s rise from penniless immigrant in 1940 to billionaire tycoon is the consummate success story in Hong Kong, a city which progressed alongside him from trading outpost to one of the world’s biggest financial centers.
SWRAY HUWHF SWRBY CKHUF CKHUY SWRBF SWRAF 0001

0
A factory worker at 13, Hong Kong's iconic billionaire retires - Channel NewsAsia

2018-03-16 channelnewsasia
Li Ka-shing's rise from penniless immigrant in 1940 to billionaire tycoon is the consummate success story in Hong Kong, a city which progressed alongside him from trading outpost to one of the world's biggest financial centers.
SWRAY HUWHF SWRBY CKHUF CKHUY SWRBF SWRAF 0001

3
Hong Kong’s Richest Man Li Ka-shing Retires - Bloomberg

2018-03-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
HCS.PRB HUWHF HGKGF HGKGY CKHUY HUSKF HCS 0001 DUE HSB HSE 0005 CKHUF HSEA HSEB HSBC.PRA DUETF HSBC HBCYF

0
Who is Li Ka-shing? Hong Kong's richest man retires

2018-03-16 cnbc
Billionaire Li Ka-shing — Asia's "superman" — is hanging up his cape after a storied career as one of the most successful businessmen in the region.
0001

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...